Image

9:12 PM / Tuesday January 31, 2023

6 Jan 2023

Probe: Alzheimer’s drug approval ‘rife with irregularities’

  • Facebook
  • Twitter
January 6, 2023 Category: Week In Review Posted by:

ABOVE PHOTO: This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday, Dec. 29, 2022, as congressional investigators called the process “rife with irregularities.” (Biogen via AP, File)

ASSOCIATED PRESS 

WASHINGTON — The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”

The 18-month investigation by two House committees detailed “atypical collaboration” between FDA regulators and a company it’s supposed to oversee — Aduhelm manufacturer Biogen. The probe also cited Biogen documents saying the company intended to “make history” when it set what investigators called an “unjustifiably high” initial price of $56,000 a year for the drug.

The criticism comes as the FDA is expected to decide whether to approve another new Alzheimer’s drug in January. Last Thursday’s report urged the agency to “take swift action” to ensure that any future Alzheimer’s approvals aren’t met with “the same doubts about the integrity of FDA’s review.”

The FDA and Biogen issued statements last Thursday defending the Aduhelm approval process.

In 2021, the FDA overruled its own independent scientific advisers when it approved Aduhelm even though research studies failed to prove it really helped patients. Biogen had halted two studies after disappointing results suggested the drug wasn’t slowing Alzheimer’s inevitable worsening — only to later contend that a new analysis of one study showed higher doses offered an incremental benefit.

The FDA argued the drug’s ability to reduce a hallmark of Alzheimer’s, a buildup of plaque in the brain, suggested it was likely to slow the disease. Backlash was immediate as three FDA advisers resigned in protest and the agency’s then-acting chief called for an internal investigation. Eventually Medicare refused to pay for the drug — even after the yearly price was dropped to $28,000 — unless patients enrolled in clinical trials to prove if it indeed slowed cognitive decline.

Thursday’s report said FDA and Biogen engaged in an unusually high volume of phone calls, meetings and emails, some of them not properly documented. In addition, the regulators and company spent months working together to prepare a briefing document for FDA’s advisers that didn’t adequately represent substantial disagreement within the FDA about how to handle Aduhelm, the report said.

The investigators recommended that FDA take steps to restore trust in the approval process that include properly documenting interactions with drugmakers. 

They also urged manufacturers to take into account advice from patient groups and other outside experts on fair drug pricing.

In a statement lastThursday, FDA said the Aduhelm decision “was based on our scientific evaluation of the data” and that the agency’s own internal review found its interactions with Biogen were appropriate. But it said it plans to update guidance on Alzheimer’s drug development and will review the investigation’s findings.

In its own statement, Biogen said: “Alzheimer’s is a highly complex disease and we have learned from the development and launch of Aduhelm” but that it “stands by the integrity of the actions we have taken.”

  • Facebook
  • Twitter

Leave a Comment

Recent News

Local

Office of Economic Opportunity debuts virtual educational series to advance pathways toward generational wealth

January 30, 2023

Tweet Share Pin Email  PHILADELPHIA – The Department of Commerce, Office of Economic Opportunity (OEO) is advancing...

Suburban News

Black History Month events in Montgomery County 

January 30, 2023

Tweet Share Pin Email Here is a listing of this year’s upcoming events. All will be held...

Stateside

Pennsylvanians encouraged to use myPATH to file 2022 PA tax returns

January 30, 2023

Tweet Share Pin Email With the opening of tax filing season, the Department of Revenue is encouraging...

Color Of Money

Preparing for tax season: Three tips to keep your documents organized

January 27, 2023

Tweet Share Pin Email BPT Taxes can be a daunting task. Some people are so anxious that...

Health

What is DME and why it matters if you have diabetes

January 27, 2023

Tweet Share Pin Email BPT Whether you have Type 1 or Type 2 diabetes, or are a...

Food And Beverage

What’s Cookin’? 7 Bean Stew

January 27, 2023

Tweet Share Pin Email Tweet Share Pin Email Related Posts What’s Cookin’?: 7 Bean Stew What’s Cookin’?...

The Philadelphia Sunday Sun Staff